Image

Study of NXP900 With Lorlatinib in ALK+ Lung Cancer

Study of NXP900 With Lorlatinib in ALK+ Lung Cancer

Recruiting
All
Phase 1
  • Technical (Original)
  • Simplified (AI rewritten)

Powered by AI

Overview

This is a multi-center, open label, Phase 1b study of NXP900 in combination with lorlatinib in subjects with advanced, ALK-positive non-small cell lung cancer (NSCLC)

Eligibility

Inclusion Criteria:

  • 18 years old or older
  • Unresectable, metastatic or locally advanced ALK-positive NSCLC.
  • Must have received lorlatinib as first or second line TKI
  • One prior line of systemic chemotherapy is permitted
  • Must have tolerated the dose level of lorlatinib actively being explored in the study or a higher dose

Exclusion Criteria:

  • Known single or compound ALK domain mutations that cause resistance to lorlatinib, or known actionable oncogenic driver alterations other than ALK with approved targeted therapies available, such as, MET or EGFR mutations or HER2 overexpression
  • Any contraindications to treatment with lorlatinib according to the lorlatinib United States Prescribing Information (USPI)

Study details
    ALK Positive
    ALK Positive Non-small Cell Lung Cancer
    NSCLC
    ALK+ Non-Small-Cell Lung Carcinoma

NCT07784959

Nuvectis Pharma, Inc.

29 August 2026

Contact a study center
Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.